journal
MENU ▼
Read by QxMD icon Read
search

Inflammatory Bowel Diseases

journal
https://read.qxmd.com/read/30776300/paradoxical-arthritis-in-inflammatory-bowel-diasease-patients-on-ustekinumab-treatment
#1
M J García García, M Rivero Tirado, M E Peiró Callizo
No abstract text is available yet for this article.
February 19, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30776076/actual-anti-tnf-trough-levels-relate-to-serum-il-10-in-drug-responding-patients-with-crohn-s-disease
#2
Pedro Zapater, Susana Almenara, Ana Gutiérrez, Laura Sempere, Marifé García, Raquel Laveda, Antonio Martínez, Michael Scharl, José I Cameo, Raquel Linares, José M González-Navajas, Reiner Wiest, Gerhard Rogler, Rubén Francés
BACKGROUND: Patients with Crohn's disease (CD) responding to anti-tumor necrosis factor (anti-TNF) show great variability in serum drug levels, even within the therapeutic range. We aimed at exploring the role of inflammatory, genetic, and bacterial variables in relation to anti-TNF through levels in CD patients. METHODS: Consecutive CD patients receiving stable doses of infliximab or adalimumab were included. Clinical and analytical parameters were recorded. Cytokine response, bacterial DNA translocation, and several immune-related genes' genotypes were evaluated, along with serum through anti-TNF drug levels...
February 19, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30772902/untargeted-metabolomics-and-inflammatory-markers-profiling-in-children-with-crohn-s-disease-and-ulcerative-colitis-a-preliminary-study
#3
Urszula Daniluk, Jaroslaw Daniluk, Rafal Kucharski, Tomasz Kowalczyk, Karolina Pietrowska, Paulina Samczuk, Aleksandra Filimoniuk, Adam Kretowski, Dariusz Lebensztejn, Michal Ciborowski
BACKGROUND: Metabolic profiling might be used to identify disease biomarkers. The aim of our study was to determine the usefulness of untargeted metabolomics analysis to detect differences in serum metabolites between newly diagnosed and untreated pediatric patients with Crohn's disease (CD) or ulcerative colitis (UC) in comparison with a control group (Ctr). Moreover, we investigated the potential of profiling metabolomics and inflammatory markers to improve the noninvasive diagnosis of CD and UC in children...
February 17, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30772910/successful-eus-guided-drainage-of-a-persistent-subdiaphragmatic-fluid-collection-in-a-patient-with-crohn-s-disease
#4
C Roberto Simons-Linares, Prabhleen Chahal
No abstract text is available yet for this article.
February 15, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30753481/silibinin-retards-colitis-associated-carcinogenesis-by-repression-of-cdc25c-in-mouse-model
#5
Weiwei Li, Xinhua Zhao, Xue Lv, Wenxiao Han, Hongying Wang
Purpose: Silibinin possesses the efficacy of anticancer and anti-inflammation. We aimed to test whether silibinin could prevent colitis-associated carcinogenesis in mouse model. Experimental Design: Azoxymethane (AOM) and dextran sulfate sodium (DSS) were used to induce colitis-associated tumorigenesis in C57BL mice. Six-to-eight-week-old male mice were gavaged with 350 or 750 mg/kg of silibinin for 10 weeks right after DSS administration. The mice were then sacrificed, and colon tissues were measured for tumor multiplicity and size...
February 11, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30753560/the-influence-of-preoperative-medications-on-postoperative-complications-in-patients-after-intestinal-surgery-for-crohn-s-disease
#6
Chang Sik Yu, Sung Woo Jung, Jong Lyul Lee, Seok-Byung Lim, In Ja Park, Yong Sik Yoon, Chan Wook Kim, Suk Kyun Ynag, Byung Duk Ye, Sang Hyung Park, Minkyu Han, Jin Cheon Kim
Background: Many patients with Crohn's disease (CD) are treated with medications, including steroids, immunomodulators, and anti-tumor necrosis factor alpha (anti-TNF-α) agents, at the time of surgery. This study evaluated the effects of these medications on postoperative complications in CD patients. Methods: This retrospective study analyzed patients who underwent bowel resection for CD between January 2006 and December 2015. Postoperative complications were defined as a Clavien-Dindo classification of grade 2A or higher within the first 30 days after surgery...
February 8, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30753551/advocating-for-patients-with-inflammatory-bowel-disease-how-to-navigate-the-prior-authorization-process
#7
Shubha Bhat, Toni Zahorian, Regine Robert, Francis A Farraye
In an effort to manage health care costs and avoid improper medication use, prior authorizations (PAs) have become a standard stipulation required by payers in the determination of medication coverage. For gastroenterologists managing patients, especially those with inflammatory bowel disease (IBD), the PA process is time-consuming and further complicated by 2 additional factors: step therapy requirements and failure of payers to recognize updated IBD treatment pathways. These factors often lead to PA denials and cause treatment delays, which in turn can lead to disease progression, ongoing patient suffering, and ultimately an increase in both direct and indirect total costs...
February 8, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30753510/adalimumab-effectiveness-up-to-six-years-in-adalimumab-na%C3%A3-ve-patients-with-crohn-s-disease-results-of-the-pyramid-registry
#8
Edward V Loftus, Walter Reinisch, Remo Panaccione, Sofie Berg, Gabriela Alperovich, Mareike Bereswill, Jasmina Kalabic, Joel Petersson, Roopal Thakkar, Anne M Robinson, Geert D'Haens
Background: PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice. Methods: Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience were enrolled in the registry and followed for up to 6 years. Effectiveness measurements included the Physician's Global Assessment (PGA, a composite of Harvey Bradshaw Index [HBI] and rectal bleeding score), clinical remission (HBI < 5), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and Work Productivity and Activity Impairment (WPAI) questionnaire...
February 8, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30753482/colonic-epithelial-surfactant-protein-d-expression-correlates-with-inflammation-in-clinical-colonic-inflammatory-bowel-disease
#9
Anders B Nexoe, Bartosz Pilecki, Sebastian Von Huth, Steffen Husby, Andreas A Pedersen, Sönke Detlefsen, Niels Marcussen, Jesper B Moeller, Uffe Holmskov, Grith L Sorensen
Background: Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract. Surfactant protein D (SP-D) is expressed in the intestinal epithelium and is essential for innate host defense and regulation of inflammatory responses. Genetic variations of SP-D are associated with IBD, but the effects of SP-D in clinical disease development have not been clarified. We hypothesized that colonic epithelial SP-D expression is increased in parallel with intestinal inflammation with the capacity to dampen deleterious effects...
February 8, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30753466/immunogenicity-of-golimumab-and-its-clinical-relevance-in-patients-with-ulcerative-colitis
#10
Omoniyi J Adedokun, George R Gunn, Jocelyn H Leu, Cynthia Gargano, Zhenhua Xu, William J Sandborn, Paul Rutgeerts, Gopi Shankar
Background: Antidrug antibody (ADA) detection with standard bridging enzyme immunoassays (EIA) can yield false-negative results or underestimate titers through drug interference. A more sensitive assay was needed to determine clinical impact of antigolimumab antibodies. Methods: A high-sensitivity, drug-tolerant EIA (DT-EIA) was developed and cross-validated against the original EIA, and samples from induction/maintenance studies in golimumab-treated patients with ulcerative colitis were analyzed for ADAs using both methods...
February 8, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30753456/successful-treatment-of-pyoderma-gangrenosum-with-concomitant-tofacitinib-and-infliximab
#11
Martin H Gregory, Matthew A Ciorba, Parakkal Deepak, George P Christophi
No abstract text is available yet for this article.
February 8, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30753443/a-user-friendly-prediction-tool-to-identify-colectomy-risk-in-patients-with-ulcerative-colitis
#12
Rahul S Dalal, Mark T Osterman, Anna M Buchner, Amy Praestgaard, James D Lewis, Gary R Lichtenstein
Background: Many patients with ulcerative colitis (UC) fear the potential side effects of immunosuppressive therapies. However, those with medically refractory disease often require total proctocolectomy (TPC) with a permanent ostomy or pouch, which may reduce quality of life. Prior studies have identified TPC predictors; however, no clinically useful prognostic tools exist to guide shared therapeutic decision-making. We therefore sought to develop a prediction tool of future TPC risk in UC patients...
February 8, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30726913/a-longitudinal-study-of-sexual-function-in-women-with-newly-diagnosed-inflammatory-bowel-disease
#13
Eugenia Shmidt, Mayte Suárez-Fariñas, Meaghan Mallette, Heather Moniz, Renee Bright, Samir A Shah, Marjorie Merrick, Jason Shapiro, Fang Xu, Bruce Sands, Sumona Saha
Background: The literature provides conflicting data on sexual function in women with inflammatory bowel disease (IBD). We aim to describe sexual function at baseline and over time in a prospective inception cohort of adult women with IBD. Methods: Women age 18 years or older enrolled in the Ocean State Crohn's & Colitis Area Registry (OSCCAR) with 2 years of prospective follow-up were included in the study. All subjects were enrolled within 1 year of IBD diagnosis...
February 6, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30715364/efficacy-of-combination-antibiotic-therapy-for-refractory-pediatric-inflammatory-bowel-disease
#14
Jessica Breton, Arthur Kastl, Natalie Hoffmann, Rachel Rogers, Andrew B Grossman, Petar Mamula, Judith R Kelsen, Robert N Baldassano, Lindsey Albenberg
Background: Recent studies have shown that oral combination antibiotics may improve disease course in refractory inflammatory bowel disease (IBD). Here, we describe the use of combination oral antibiotics as salvage therapy in refractory ulcerative colitis (UC), Crohn's colitis, and IBD-unclassified (IBD-U) at a large pediatric IBD center. Methods: Clinical response, disease activity indices, adverse events, and clinical outcomes were measured up to 1 year after antibiotic treatment in this retrospective cohort study of children with medically refractory IBD colitis...
February 4, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30698787/regain-of-response-to-adalimumab-in-a-steroid-dependent-pediatric-patient-with-ulcerative-colitis-after-undergoing-selective-granulocyte-and-monocyte-apheresis
#15
Marta Velasco Rodríguez-Belvís, Javier Francisco Viada Bris, Laura Palomino Pérez, Rosa Ana Muñoz Codoceo
No abstract text is available yet for this article.
January 30, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30698715/the-incidence-and-definition-of-crohn-s-disease-of-the-pouch-a-systematic-review-and-meta-analysis
#16
Edward L Barnes, Bharati Kochar, Hilary R Jessup, Hans H Herfarth
Background: A subset of patients who undergo total proctocolectomy with ileal pouch-anal anastomosis (IPAA) creation for ulcerative colitis (UC) will later develop Crohn's disease (CD) of the pouch, which has been associated with significant morbidity. We aimed to analyze the incidence of CD of the pouch and to review the existing diagnostic criteria utilized. Methods: A systematic search performed through March 1, 2018, identified 12 studies that reported the incidence of CD of the pouch after IPAA for UC or indeterminate colitis (IC)...
January 30, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30698700/microbiota-nourishing-immunity-and-its-relevance-for-ulcerative-colitis
#17
Mariana X Byndloss, Yael Litvak, Andreas J Bäumler
No abstract text is available yet for this article.
January 30, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30689871/psychological-characteristics-of-inflammatory-bowel-disease-patients-a-comparison-between-active-and-nonactive-patients
#18
Daniela Leone, Daniela Gilardi, Bianca E Corrò, Julia Menichetti, Elena Vegni, Carmen Correale, Allocca Mariangela, Federica Furfaro, Stefanos Bonovas, Laurent Peyrin-Biroulet, Silvio Danese, Gionata Fiorino
Background and aims: The role of new psychological factors such as psychopathological patterns and defense mechanisms in the care of inflammatory bowel disease (IBD) has been poorly investigated. We aimed to assess the psychological characteristics and defense mechanisms of IBD patients. Methods: This was a single-center, observational, cross-sectional study. Consecutive adult IBD patients were enrolled and stratified according to disease activity. Sociodemographic and clinical data were collected, and validated questionnaires (Symptom Checklist-90-R [SCL-90-R]) for psychological distress, Defense Mechanism Inventory (DMI) for psychological defense mechanisms, and Inflammatory Bowel Disease Questionnaire (IBDQ) for quality of life (QoL) were administered...
January 28, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30689858/systematic-review-cost-effective-strategies-of-optimizing-anti-tumor-necrosis-and-immunomodulators-in-inflammatory-bowel-disease
#19
Abhinav Vasudevan, Peter R Gibson, Daniel R Van Langenberg
Background: Medication costs in inflammatory bowel disease (IBD) are now the principal driver of health care costs. Cost-effective strategies to optimize and rationalize treatment are therefore necessary. Methods: A systematic review until April 30, 2018, was performed to identify economic evaluations of strategies to optimize infliximab, adalimumab, and immunomodulators for the treatment of IBD in adults. A qualitative synthesis of the identified studies was performed...
January 25, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30668755/a-jak1-selective-kinase-inhibitor-and-tofacitinib-affect-macrophage-activation-and-function
#20
L C S De Vries, J M Duarte, M De Krijger, O Welting, P H P Van Hamersveld, F W M Van Leeuwen-Hilbers, P D Moerland, A Jongejan, G R D'Haens, W J De Jonge, M E Wildenberg
Background: Janus kinases (JAKs) mediate cytokine signaling involved in inflammatory bowel disease. The pan-JAK inhibitor tofacitinib has shown efficacy in the treatment of ulcerative colitis. However, concerns regarding adverse events due to their wide spectrum inhibition fueled efforts to develop selective JAK inhibitors. Given the crucial role of myeloid cells in intestinal immune homeostasis, we evaluated the effect of pan-JAK and selective JAK inhibitors on pro- and anti-inflammatory macrophage polarization and function (M1/M2) and in experimental colitis...
January 19, 2019: Inflammatory Bowel Diseases
journal
journal
32277
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"